EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pharmacological Management of Sleep–Wake Disturbances in Delirium

Erik A Levinsohn iD, Varsha Radhakrishnan, Haley Euting, Gary B Kaplan

The Journal of Clinical Pharmacology · 2025

DOI: 10.1002/jcph.6151 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Erik A Levinsohn und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of California San Francisco Medical Center, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Delirium, Sleep Wake Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 141 Literaturangaben. Gefördert von: U.S. Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Delirium is a heterogeneous syndrome primarily characterized by fluctuations in attention and awareness. Sleep–wake disturbances are a common and significant feature of delirium and can manifest as circadian rhythm inversion, sleep fragmentation, and reduced rapid eye movement (REM) and slow‐wave sleep. Some literature suggests that the relationship between sleep disruption and delirium is reciprocal wherein the two reinforce one another and may share an underlying etiology. As there are no FDA‐approved medications for delirium or delirium‐related sleep disturbances, management is primarily focused on addressing underlying medical concerns and promoting physiologic circadian patterns with non‐pharmacological behavioral interventions. In practice, however, medications are often used, albeit with limited evidence to support their use. This literature review explores the pharmacology and pharmacokinetics of several medications with literature investigating their use in delirium: melatonin, ramelteon, dual orexin receptor antagonists (DORAs), and dexmedetomidine. Current evidence suggests a possible benefit of ramelteon or melatonin, dexmedetomidine for patients in the ICU setting, and DORAs as therapeutic options for the re‐regulation of sleep–wake cycle disruption in delirium. We discuss pertinent pharmacokinetic and pharmacodynamic factors that may influence clinical decision‐making regarding these interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeliriumSleep Wake DisordersHumansMelatoninOrexin Receptor AntagonistsIndenesDexmedetomidine

Stichwörter der Autor:innen

DORAdeliriumdexmedetomidineinsomniamelatoninramelteon

Substanzen

MelatoninramelteonOrexin Receptor AntagonistsIndenesDexmedetomidine

Autor:innen und Institutionen

  • Department of Psychiatry, University of California San Francisco Medical Center, San Francisco, CA, USA.
  • Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
  • Department of Psychiatry, Tufts Medical Center, Boston, MA, USA.
  • Department of Psychiatry, Tufts University School of Medicine, Boston, MA, USA.
  • Psychiatry Service, VA Boston Healthcare System, West Roxbury, MA, USA.
  • Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, USA.

ORCID-Profile: Erik A Levinsohn

Förderung

  • U.S. Department of Veterans Affairs

Zitieren

APA

Levinsohn, E. A., Radhakrishnan, V., Euting, H., & Kaplan, G. B. (2025). Pharmacological Management of Sleep–Wake Disturbances in Delirium. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6151

Vancouver

Levinsohn EA, Radhakrishnan V, Euting H, Kaplan GB. Pharmacological Management of Sleep–Wake Disturbances in Delirium. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.6151

BibTeX
@article{Levinsohn2025,
  author = {Levinsohn, Erik A and Radhakrishnan, Varsha and Euting, Haley and Kaplan, Gary B},
  title = {Pharmacological Management of Sleep–Wake Disturbances in Delirium},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/jcph.6151}
}
Kostenlos starten →